All Publications from Accelerate Diagnostics
Investor Relations
Presentations & Press Releases
Stock Info
SEC Filings
Corporate Governance
Accelerate Diagnostics Schedules First-Quarter 2016 Results Announcement and Webcast

TUCSON, Ariz.April 25, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today it will report first-quarter 2016 financial results after market close on Thursday, May 12, 2016.

President and Chief Executive Officer, Lawrence Mehren, joined by Steve Reichling, Chief Financial Officer, will host an audio webcast to review the first-quarter results that same day at 4:00 PM Eastern.

To access the audio webcast visit the company's website at or listen to a replay of the webcast during the week following the announcement.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. ("Accelerate Diagnostics,") (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and hospital acquired infections. The company's fully automated ID/AST system, Accelerate Pheno™, and direct from positive blood culture test, Accelerate PhenoTest™ BC, utilize proprietary molecular and phenotypic detection technologies which have the potential to substantially reduce the time to antimicrobial susceptibility results while achieving high sensitivity and specificity. For more information about Accelerate Diagnostics, visit

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, about our projections as to when certain key business milestones may be achieved, including completion of the trial intended to support marketing authorization by the FDAof the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the commercial launch of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the potential of our technology, the growth of the market, our estimates as to the size of our market opportunity and potential pricing, our competitive position and estimates of time reduction to results, and our future development plans and growth strategy. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016. In addition, the company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.



Media Contact:

Andrew Chasteen

+1 (520) 365 3100

Investor Contact:

Laura Pierson

+1 (520) 365 3100



Source:  Accelerate Diagnostics, Inc.


News Provided by Acquire Media